Cogent Biosciences Inc (COGT)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $4.97B
Last updated: Nov 17, 2026 at 4:20 PM ET
Cogent Biosciences Inc (COGT) Statistics
Cogent Biosciences (COGT) has a market cap of $4.97B and an enterprise value of $4.98B. Its share count is up 23.81% from a year earlier. Revenue fell 100.00% over the last 12 months from the 12 months before.
Total Valuation
Enterprise value is 0.16% above the market cap, as debt exceeds cash.
| Market Cap | $4.97B |
|---|---|
| Enterprise Value | $4.98B |
| Latest price (Nov 17, 2026) | $27.85 |
Key Dates
The next earnings report is expected on Feb 15, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Feb 15, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 5, 2026 |
| Fiscal Year End | December |
Valuation Ratios
| Forward P/S | 952.5x |
|---|---|
| P/B Ratio | 9.3x |
Price Statistics
The stock is down 16.96% over 52 weeks and trades 10.45% below its 50-day average.
| Beta (1Y) | 1.36 |
|---|---|
| 52-Week Change | -16.96% |
| 1-Month Change | -7.20% |
| 3-Month Change | -24.42% |
| 6-Month Change | -10.88% |
| 5-Year Change | +265.80% |
| Total Return (1Y) | -16.96% |
| Total Return (3Y CAGR) | +51.67% |
| Total Return (5Y CAGR) | +22.10% |
| Return vs SPY (1Y) | -28.18% |
| Max Drawdown (1Y) | -35.95% |
| Max Drawdown (3Y) | -67.32% |
| Sharpe Ratio (1Y) | -0.40 |
| Correlation with SPY (1Y) | 0.41 |
| 50-Day Average | $31.10 |
| 200-Day Average | $35.21 |
| 52-Week Range | $27.23 to $43.73 |
| RSI (14 Days) | 39.4 |
| Average Volume (20 Days) | 2.10M |
The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 10.99x current liabilities, and total debt is 0.44x shareholder equity.
| Current Ratio | 10.99x |
|---|---|
| Quick Ratio | 10.99x |
| Debt / Equity | 0.44x |
| Interest Coverage | -82.07x |
Returns and Efficiency
Return on invested capital is -43.38% over the last 12 months, against a 5-year average of -50.90%.
| Return on Equity (ROE) | -78.97% |
|---|---|
| Return on Assets (ROA) | -48.99% |
| Return on Invested Capital (ROIC) | -43.38% |
| Return on Capital Employed (ROCE) | -53.65% |
| ROE (5Y Average) | -62.35% |
| ROA (5Y Average) | -49.95% |
| ROIC (5Y Average) | -50.90% |
Scores
COGT has a Piotroski F-Score of 3 of 9, in the average band of 3 to 7.
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Piotroski F-Score | 3 of 9 |
|---|---|
| Piotroski Strength | Average |
Income Statement
Revenue was $0 over the last 12 months.
| Revenue | $0 |
|---|---|
| Revenue Growth (YoY) | -100.00% |
| Operating Income | -$422.92M |
| Pretax Income | -$407.68M |
| Net Income | -$407.68M |
| EBITDA | -$403.64M |
| EBIT | -$407.25M |
| Reported EPS (TTM) | -$2.20 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 62.04% of the $832.14M in total assets.
| Cash and Equivalents | $217.46M |
|---|---|
| Total Debt | $225.32M |
| Net Debt | $7.86M |
| Net Debt Per Share | $0.05 |
| Working Capital | $730.47M |
| Shareholder Equity | $516.26M |
| Book Value Per Share | $2.98 |
| Total Assets | $832.14M |
| Total Liabilities | $315.88M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $1.74M of capital spending, operating cash flow left -$325.78M of free cash flow.
| Operating Cash Flow | -$324.05M |
|---|---|
| Capital Expenditures | $1.74M |
| Free Cash Flow | -$325.78M |
| FCF Per Share | -$1.87 |
| Depreciation and Amortization | $3.61M |
Trailing 12 months through Sep 30, 2026.
Growth
| Book Value Per Share Growth (2Y CAGR) | +15.32% |
|---|---|
| Tangible Book Per Share Growth (2Y CAGR) | +15.32% |
Dividends and Yields
COGT does not pay a dividend. Its free cash flow yield is -6.76%.
| FCF Yield | -6.76% |
|---|---|
| Shareholder Yield | 0.00% |
Stock Splits
The last split was a 1-for-4 reverse split on Nov 9, 2020.
| Last Split Date | Nov 9, 2020 |
|---|---|
| Split Type | Reverse split |
| Split Ratio | 1:4 |
Peer Position
Against 9 similar companies, COGT has the 9th highest ROIC.
ROICPeer median -25.19%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median -34.34%
| ROIC | -43.38% vs -25.19% median |
|---|---|
| Revenue Growth (Trailing 4 Quarters, YoY) | -100.00% vs -34.34% median |
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About COGT
What is COGT's market cap?
Cogent Biosciences has a market cap of $4.97B. Its enterprise value, which adds debt and subtracts cash, is $4.98B.
How many shares of COGT are outstanding?
Cogent Biosciences has 173.13M shares outstanding. The count is up 23.81% from a year earlier.
Does COGT pay a dividend?
No. Cogent Biosciences does not pay a dividend.
How much debt does COGT have?
Cogent Biosciences has $225.32M of total debt and $217.46M of cash and equivalents, a net debt position of $7.86M.
COGT pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors